Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dose-dependent manner - 25/08/11
Abstract |
Background |
This study investigated Saratin’s (Merck KGaA, Darmstadt, Germany) prevention of platelet adhesion and intimal hyperplasia at different doses and in the hyperhomocystinemia rat carotid endarterectomy (CEA) model.
Methods |
Rats were divided into two groups: (1) platelet adhesion or (2) luminal stenosis because of intimal hyperplasia. At CEA, rats received 0, 0.5, 5.0, 10.0, or 20.0 μg Saratin on the artery. Post-CEA platelet aggregation was evaluated by standard error of the mean. Intimal hyperplasia group received either (1) control or (2) 4.5 g/kg DL-homocystine diets for two weeks followed by CEA and treated with diluent or 5.0 μg Saratin. Endpoints included platelet adhesion, intimal hyperplasia, plasma homocysteine (HCys), and its metabolic enzymes cystathionine β-synthase (CBS) and methylenetetrahydrofolate reductase (MTHFR).
Results |
Platelet adhesion: post-CEA, platelet adhesion was reduced by 63%, 67%, and 67% in Saratin doses ≥5.0 μg. Intimal hyperplasia: 5.0 μg Saratin in the HCys group decreased intimal hyperplasia by 45% compared with the non-Saratin-treated HCys group. Plasma HCys levels were not altered with Saratin treatment in the HCys groups nor were CBS or MTHFR.
Conclusions |
Saratin significantly inhibited platelet adhesion at ≥5.0 μg, and Saratin at 5.0 μg attenuated luminal stenosis in a hyperhomocysteinemic rat CEA model.
Le texte complet de cet article est disponible en PDF.Keywords : Carotid endarterectomy, Saratin, Intimal hyperplasia, Homocysteine, Platelet
Plan
Supported by Merck KGaA, Darmstadt, Germany. |
Vol 188 - N° 6
P. 778-785 - décembre 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?